<u>**LISTING OF THE CLAIMS**</u>

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-16 (Canceled)

17.   (Currently Amended)   A complex immuno-gene medical composition for inhibiting tumor cells producing TGF-β, comprising a therapeutically effective amount of a plasmid comprising a DNA sequence of SEQ ID NO: 1 encoding IL-6 and a therapeutically effective amount of a plasmid comprising a DNA sequence of SEQ ID NO: [[3]] <u>4</u> encoding IL-15 ~~linked to a~~ <u>with an IL-2</u> signal peptide.

18.   (Previously Presented)   The medical composition of claim 17, wherein the tumor cells express low or no MHC.

19.   (Previously Presented)   The medical composition of claim 17, wherein the composition inhibits the tumor cells by antagonizing TGF-β and enhancing cytotoxicity of NK cells.

20.   (Previously Presented)   The medical composition of claim 17, wherein the tumor is CTVT.

21.   (Previously Presented)   The medical composition of claim 17, wherein the plasmid is a pcDNA3.1/V5-His-TOPO vector.

22.   (Currently Amended) A method for inhibiting growth of tumor cells producing TGF-β, comprising administrating a therapeutically effective amount of a complex immuno-gene medical composition to an individual in need thereof to activate NK cells and enhance cytotoxicity of the NK cells, wherein the complex immuno-gene medical composition comprises a plasmid comprising a <u>pcDNA3.1/V5-His-TOPO vector into which is ligated a</u> DNA sequence of SEQ ID NO: 1 encoding IL-6 and a plasmid comprising a <u>pcDNA3.1/V5-His-TOPO vector into which is ligated a</u> DNA sequence of SEQ ID NO: [[3]] <u>4</u> encoding IL-15 <u>with an IL-2 signal peptide</u>, ~~wherein the plasmid~~

is a ~~pcDNA3.1/V5-His-TOPO vector,~~ and <u>wherein</u> the medical composition is administered by muscle electroporation *in vivo*.

23. (Previously Presented) The method of claim 22, wherein the tumor cells express low or no MHC.

24. (Previously Presented) The method of claim 22, wherein the tumor is CTVT.

25. (Previously Presented) The method of claim 22, wherein the individual is a mammal.

26. (Previously Presented) The method of claim 22, wherein the individual is a canine.

27. (Previously Presented) The method of claim 22, wherein the individual is a rodent.

28. (Canceled)